CO4990992A1 - Profarmacos de compuestos de sulfonamida como inhibidores de aspartil proteasa - Google Patents
Profarmacos de compuestos de sulfonamida como inhibidores de aspartil proteasaInfo
- Publication number
- CO4990992A1 CO4990992A1 CO98076458A CO98076458A CO4990992A1 CO 4990992 A1 CO4990992 A1 CO 4990992A1 CO 98076458 A CO98076458 A CO 98076458A CO 98076458 A CO98076458 A CO 98076458A CO 4990992 A1 CO4990992 A1 CO 4990992A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- optionally substituted
- independently selected
- alkenyl
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/998,050 US6436989B1 (en) | 1997-12-24 | 1997-12-24 | Prodrugs of aspartyl protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4990992A1 true CO4990992A1 (es) | 2000-12-26 |
Family
ID=25544691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98076458A CO4990992A1 (es) | 1997-12-24 | 1998-12-23 | Profarmacos de compuestos de sulfonamida como inhibidores de aspartil proteasa |
Country Status (43)
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122000A1 (en) * | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
| UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
| ID27600A (id) | 1998-06-02 | 2001-04-12 | Osi Pharm Inc | KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA |
| GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| AU6329599A (en) * | 1998-09-28 | 2000-04-17 | Glaxo Group Limited | Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester |
| GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| KR100870184B1 (ko) | 2001-02-14 | 2008-11-24 | 티보텍 파마슈티칼즈 리미티드 | 광범위 2-(치환된-아미노)-벤조티아졸 설폰아미드 ｈｉｖ프로티아제 억제제 |
| AR035819A1 (es) | 2001-04-09 | 2004-07-14 | Tibotec Pharm Ltd | 2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos |
| AU2002310818B2 (en) | 2001-05-11 | 2007-12-13 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors |
| US7576084B2 (en) * | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7504407B2 (en) | 2001-11-30 | 2009-03-17 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
| AR037797A1 (es) * | 2001-12-12 | 2004-12-01 | Tibotec Pharm Ltd | Combinacion de inhibidores de proteasa dependientes del citocromo p450 |
| EA007468B1 (ru) | 2001-12-20 | 2006-10-27 | Оси Фармасьютикалз, Инк. | Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
| CN1816551A (zh) | 2001-12-20 | 2006-08-09 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途 |
| EA009556B1 (ru) | 2001-12-21 | 2008-02-28 | Тиботек Фармасьютикалз Лтд. | Гетероциклические замещённые фенилсодержащие сульфонамиды широкого спектра действия в качестве ингибиторов протеазы вич |
| MY142238A (en) | 2002-03-12 | 2010-11-15 | Tibotec Pharm Ltd | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
| US7157489B2 (en) * | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
| CA2481449A1 (en) * | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Method and compositions for identifying anti-hiv therapeutic compounds |
| KR101019648B1 (ko) | 2002-05-17 | 2011-03-07 | 티보텍 파마슈티컬즈 | 광범위 스펙트럼의 치환된 벤즈이속사졸 설폰아미드ｈｉｖ 프로테아제 저해제 |
| PL375307A1 (en) | 2002-08-14 | 2005-11-28 | Tibotec Pharmaceuticals Ltd. | Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| CA2425031A1 (en) * | 2003-04-01 | 2004-10-01 | Smithkline Beecham Corporation | Pharmaceutical compositions |
| EP1620109A2 (en) | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| PL1628685T3 (pl) | 2003-04-25 | 2011-05-31 | Gilead Sciences Inc | Przeciwwirusowe analogi fosfonianowe |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
| EP2298323A3 (en) | 2003-07-09 | 2011-05-11 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| US20050137174A1 (en) * | 2003-07-09 | 2005-06-23 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| US20050119163A1 (en) * | 2003-09-18 | 2005-06-02 | The Government Of The United States Of America, As Represented By The Secretary, | SH2 domain binding inhibitors |
| US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
| US8193227B2 (en) | 2003-12-11 | 2012-06-05 | Abbott Laboratories | HIV protease inhibiting compounds |
| US7834043B2 (en) * | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
| CN102627609B (zh) * | 2003-12-15 | 2016-05-04 | 默沙东公司 | 杂环天冬氨酰蛋白酶抑制剂 |
| US7799772B2 (en) | 2003-12-18 | 2010-09-21 | Janssen Pharmaceutica N.V. | Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents |
| WO2005063751A1 (en) | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | 4’-substituted carbovir-and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity |
| US7718633B2 (en) * | 2004-07-06 | 2010-05-18 | Abbott Laboratories | Prodrugs of HIV protease inhibitors |
| DK1778251T3 (da) | 2004-07-27 | 2011-07-18 | Gilead Sciences Inc | Nukleosidphosphatkonjugater som anti-HIV-midler |
| US7388008B2 (en) * | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| BRPI0418651A (pt) * | 2004-08-02 | 2007-05-29 | Ambrilia Biopharma Inc | compostos com base em lisina |
| EP1789107B1 (en) | 2004-08-30 | 2009-05-27 | Interstitial Therapeutics | Medical stent provided with inhibitors of atp synthesis |
| CN101098698A (zh) | 2004-12-01 | 2008-01-02 | 德福根有限公司 | 与离子通道尤其是Kv家族离子通道相互作用的5-羧酰胺基取代的噻唑衍生物 |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| JP4326575B2 (ja) | 2004-12-17 | 2009-09-09 | デブゲン・エヌ・ブイ | 殺線虫性組成物 |
| AU2006206458B2 (en) * | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| JP2008533017A (ja) * | 2005-03-11 | 2008-08-21 | スミスクライン ビーチャム コーポレーション | Ｈｉｖプロテアーゼ阻害薬 |
| AR053845A1 (es) | 2005-04-15 | 2007-05-23 | Tibotec Pharm Ltd | 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450 |
| US20060287316A1 (en) * | 2005-04-27 | 2006-12-21 | Ambrilia Biopharma Inc. | Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors |
| WO2007045496A1 (en) | 2005-10-21 | 2007-04-26 | Universiteit Antwerpen | Novel urokinase inhibitors |
| AR057182A1 (es) | 2005-11-28 | 2007-11-21 | Tibotec Pharm Ltd | Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih |
| TWI432438B (zh) | 2005-11-28 | 2014-04-01 | Tibotec Pharm Ltd | 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物 |
| PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
| ES2452718T3 (es) * | 2005-11-30 | 2014-04-02 | Taimed Biologics, Inc. | Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación |
| EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| JP4644287B2 (ja) * | 2005-12-27 | 2011-03-02 | 大塚製薬株式会社 | 水溶性ベンゾアゼピン化合物及び医薬組成物 |
| AU2007274284B2 (en) | 2006-07-13 | 2012-04-26 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
| CA2662449A1 (en) | 2006-09-08 | 2008-03-13 | Bayer Schering Pharma Aktiengesellschaft | Compounds and methods for 18f labeled agents |
| CA2664118A1 (en) | 2006-09-21 | 2008-07-03 | Ambrilia Biopharma Inc. | Protease inhibitors |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| WO2008112289A2 (en) | 2007-03-12 | 2008-09-18 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
| EP2185562B1 (en) | 2007-07-27 | 2015-12-02 | Janssen Pharmaceutica, N.V. | Pyrrolopyrimidines useful for the treatment of proliferative diseases |
| EP2053033A1 (en) | 2007-10-26 | 2009-04-29 | Bayer Schering Pharma AG | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| DK2283024T3 (da) | 2008-03-10 | 2013-08-05 | Janssen Pharmaceutica Nv | 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer |
| US9095620B2 (en) * | 2008-03-12 | 2015-08-04 | Nektar Therapeutics | Reagents |
| EP2116236A1 (en) | 2008-04-21 | 2009-11-11 | Université de Mons-Hainaut | Bisbenzamidine derivatives for use as antioxidant |
| CN102089318B (zh) | 2008-07-08 | 2014-05-21 | 吉里德科学公司 | Hiv抑制剂化合物的盐 |
| PL2364314T3 (pl) | 2008-12-09 | 2014-08-29 | Gilead Sciences Inc | Modulatory receptorów Toll-podobnych |
| US20120135965A1 (en) * | 2009-05-20 | 2012-05-31 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
| WO2010144869A2 (en) | 2009-06-12 | 2010-12-16 | Nektar Therapeutics | Protease inhibitors |
| EP2477996A1 (en) | 2009-09-16 | 2012-07-25 | Ranbaxy Laboratories Limited | Process for the preparation of fosamprenavir calcium |
| WO2011061590A1 (en) | 2009-11-17 | 2011-05-26 | Hetero Research Foundation | Novel carboxamide derivatives as hiv inhibitors |
| EP2501431B1 (en) | 2009-11-19 | 2020-01-08 | Wellinq Medical B.V. | Narrow profile composition-releasing expandable medical balloon catheter |
| WO2011085130A1 (en) | 2010-01-07 | 2011-07-14 | Pliva Hrvatska D.O.O. | Solid state forms of fosamprenavir calcium salt and process for preparation thereof |
| EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
| US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
| US20110224443A1 (en) * | 2010-03-15 | 2011-09-15 | Venkata Naga Brahmeshwara Rao Mandava | Preparation of fosamprenavir calcium |
| WO2011114212A1 (en) | 2010-03-19 | 2011-09-22 | Lupin Limited | Ammonium, calcium and tris salts of fosamprenavir |
| JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
| WO2011141515A1 (en) | 2010-05-14 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Diagnostic agents for amyloid beta imaging |
| US20130211108A1 (en) | 2010-06-18 | 2013-08-15 | Mylan Laboratories Ltd | Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts |
| US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
| EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
| EP2614055A2 (en) * | 2010-09-10 | 2013-07-17 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
| GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
| WO2012085625A1 (en) | 2010-12-21 | 2012-06-28 | Lupin Limited | Process for the preparation of fosamprenavir calcium and intermediate used in its preparation |
| WO2012107937A2 (en) * | 2011-02-10 | 2012-08-16 | Mylan Laboratories Ltd | Crystalline fosamprenavir calcium and process for the preparation thereof" |
| SG10201800715PA (en) | 2011-06-21 | 2018-02-27 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
| WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
| US9309213B2 (en) | 2011-07-11 | 2016-04-12 | Purdue Research Foundation | C-3 substituted bicyclooctane based HIV protease inhibitors |
| WO2013011485A1 (en) | 2011-07-20 | 2013-01-24 | Ranbaxy Laboratories Limited | Process for the preparation of sulfonamides useful as retroviral protease inhibitors |
| IN2012DE00082A (US06559137-20030506-C00232.png) | 2012-01-10 | 2015-05-01 | Council Scient Ind Res | |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| EP2700396A3 (en) | 2012-06-20 | 2015-04-29 | Sylphar Nv | Strip for the delivery of oral care compositions |
| WO2014059034A2 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
| US9227990B2 (en) | 2012-10-29 | 2016-01-05 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
| LT2929031T (lt) | 2012-12-05 | 2018-02-12 | Alnylam Pharmaceuticals, Inc. | Pcsk9 irna kompozicijos ir jų naudojimo būdai |
| WO2014160129A2 (en) | 2013-03-14 | 2014-10-02 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| BR112015029139B1 (pt) | 2013-05-22 | 2022-07-12 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla para inibição da expressão de serpina1 em uma célula, seus usos, bem como composição farmacêutica e método in vitro de inibição da expressão de serpina1 em uma célula |
| CN105452463B (zh) | 2013-05-22 | 2019-06-21 | 阿尔尼拉姆医药品有限公司 | Tmprss6 irna组合物及其使用方法 |
| AU2014362262B2 (en) | 2013-12-12 | 2021-05-13 | Alnylam Pharmaceuticals, Inc. | Complement component iRNA compositions and methods of use thereof |
| CN113057959A (zh) | 2014-02-11 | 2021-07-02 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶（KHK）iRNA组合物及其使用方法 |
| WO2015175510A1 (en) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
| SG10202104570TA (en) | 2014-05-22 | 2021-06-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
| EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
| WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
| AU2015287773B2 (en) | 2014-07-11 | 2018-03-29 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
| US9738664B2 (en) | 2014-10-29 | 2017-08-22 | Wisconsin Alumni Research Foundation | Boronic acid inhibitors of HIV protease |
| WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| CA2968114A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| WO2016083490A1 (en) | 2014-11-27 | 2016-06-02 | Remynd Nv | Compounds for the treatment of amyloid-associated diseases |
| AU2016219263B2 (en) | 2015-02-13 | 2022-12-01 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof |
| CN107743522B (zh) | 2015-04-13 | 2022-11-11 | 阿尔尼拉姆医药品有限公司 | 类血管生成素3(ANGPTL3)iRNA组合物及其使用方法 |
| CN108025187A (zh) | 2015-04-28 | 2018-05-11 | 新南创新私人有限公司 | 靶向nad+以治疗化学疗法和放射疗法引发的认知损害、神经病变和不活动 |
| KR20180002688A (ko) | 2015-05-06 | 2018-01-08 | 알닐람 파마슈티칼스 인코포레이티드 | 인자 ＸＩＩ(하게만 인자)(Ｆ12), 칼리크레인 Ｂ, 혈장(플레처 인자) 1(ＫＬＫＢ1) 및 키니노겐 1(ＫＮＧ1) ｉＲＮＡ 조성물 및 그의 이용 방법 |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| WO2017048620A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| MA42818A (fr) | 2015-09-15 | 2018-07-25 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
| TWI743069B (zh) | 2015-12-07 | 2021-10-21 | 美商健贊公司 | 治療ｓｅｒｐｉｎｃ１相關疾患之方法及組成物 |
| JP2018536689A (ja) | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
| EP3469083A1 (en) | 2016-06-10 | 2019-04-17 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
| TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| KR20230166146A (ko) | 2016-12-16 | 2023-12-06 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법 |
| DK3621963T3 (da) | 2017-05-11 | 2024-04-15 | Remynd N V | Forbindelser til behandling af epilepsi, neurodegenerative lidelser og andre CNS-lidelser |
| WO2019016732A1 (en) | 2017-07-21 | 2019-01-24 | Viiv Healthcare Company | REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS |
| PT3661937T (pt) | 2017-08-01 | 2021-09-24 | Gilead Sciences Inc | Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais |
| AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| TW202023574A (zh) | 2018-08-13 | 2020-07-01 | 美商阿尼拉製藥公司 | Ｂ型肝炎病毒（ＨＢＶ）ｄｓＲＮＡ劑組合物及其使用方法 |
| MX2021008628A (es) | 2019-01-16 | 2021-11-17 | Genzyme Corp | Composiciones de arni para serpinc1 y metodos de uso de las mismas. |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| WO2021170600A1 (en) | 2020-02-24 | 2021-09-02 | Katholieke Universiteit Leuven | Pyrrolopyridine and imidazopyridine antiviral compounds |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| JP2024500543A (ja) | 2020-12-22 | 2024-01-09 | ルクセンブルク インスティテュート オブ ヘルス（エルアイエイチ） | がん及び循環器疾患の処置のための選択的ａｃｋｒ３調節物質としてのコノリジンアナログ |
| EP4301369A1 (en) | 2021-03-04 | 2024-01-10 | Universiteit Antwerpen | Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer |
| EP4347541A2 (en) | 2021-05-31 | 2024-04-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof |
| WO2023021132A1 (en) | 2021-08-18 | 2023-02-23 | Katholieke Universiteit Leuven | 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues |
| WO2023046900A1 (en) | 2021-09-23 | 2023-03-30 | Katholieke Universiteit Leuven | Ribonucleoside analogues against -sars-cov-2 |
| WO2023241799A1 (en) | 2022-06-15 | 2023-12-21 | Université Libre de Bruxelles | Flavanols for use in the treatment of retroviral infections |
| WO2024062043A1 (en) | 2022-09-21 | 2024-03-28 | Universiteit Antwerpen | Substituted phenothiazines as ferroptosis inhibitors |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3743722A (en) | 1971-07-14 | 1973-07-03 | Abbott Lab | Anti-coagulant isolation |
| FR2459235A1 (fr) | 1979-06-14 | 1981-01-09 | Sanofi Sa | Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique |
| JPS5946252A (ja) | 1982-09-09 | 1984-03-15 | Dainippon Ink & Chem Inc | 含フツ素アミノカルボキシレ−トおよびその製法 |
| JPS5948449A (ja) | 1982-09-13 | 1984-03-19 | Dainippon Ink & Chem Inc | 直鎖状含フツ素アニオン化合物およびその製造方法 |
| JPS6171830A (ja) | 1984-09-17 | 1986-04-12 | Dainippon Ink & Chem Inc | 界面活性剤組成物 |
| US4616088A (en) | 1984-10-29 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitor |
| US4629724A (en) | 1984-12-03 | 1986-12-16 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitors |
| DE3635907A1 (de) | 1986-10-22 | 1988-04-28 | Merck Patent Gmbh | Hydroxy-aminosaeurederivate |
| CH676988A5 (US06559137-20030506-C00232.png) | 1987-01-21 | 1991-03-28 | Sandoz Ag | |
| CA1340588C (en) | 1988-06-13 | 1999-06-08 | Balraj Krishan Handa | Amino acid derivatives |
| IL91780A (en) | 1988-10-04 | 1995-08-31 | Abbott Lab | History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them |
| WO1990007329A1 (en) | 1989-01-06 | 1990-07-12 | The Regents Of The University Of California | Selection method for pharmacologically active compounds |
| US5151438A (en) | 1989-05-23 | 1992-09-29 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IE902295A1 (en) | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| HUT64738A (en) | 1990-06-01 | 1994-02-28 | Du Pont Merck Pharma | Process for preparing 1,4-diamino-2,3-dihydroxi-butane compounds and pharmaceutical compositions contianing them |
| TW225540B (US06559137-20030506-C00232.png) | 1990-06-28 | 1994-06-21 | Shionogi & Co | |
| DK0554400T3 (da) | 1990-11-19 | 1998-02-16 | Monsanto Co | Retrovirale proteaseinhibitorer |
| ES2059294T3 (es) | 1990-11-19 | 1997-04-01 | Monsanto Co | Inhibidores de proteasas retroviricas. |
| JPH06505963A (ja) | 1990-11-19 | 1994-07-07 | モンサント カンパニー | レトロウイルスプロテアーゼ阻害剤 |
| EP0558673B1 (en) | 1990-11-19 | 1996-04-17 | Monsanto Company | Retroviral protease inhibitors |
| IE913840A1 (en) | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
| CA2081970C (en) | 1991-11-08 | 1997-07-08 | Joseph P. Vacca | Hiv protease inhibitors useful for the treatment of aids |
| AU676479B2 (en) | 1992-05-20 | 1997-03-13 | G.D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| EP1148050A1 (en) | 1992-05-21 | 2001-10-24 | Monsanto Company | Retroviral protease inhibitors |
| WO1994004492A1 (en) | 1992-08-25 | 1994-03-03 | G.D. Searle & Co. | Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| ES2112430T3 (es) | 1992-08-25 | 1998-04-01 | Searle & Co | Sulfonilalcanoilamino hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas. |
| ATE154800T1 (de) | 1992-08-25 | 1997-07-15 | Searle & Co | N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren |
| ATE186548T1 (de) * | 1992-09-03 | 1999-11-15 | Boehringer Ingelheim Pharma | Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen |
| US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| TW372972B (en) | 1992-10-23 | 1999-11-01 | Novartis Ag | Antiretroviral acyl compounds |
| EP1462443A1 (en) | 1992-10-30 | 2004-09-29 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors |
| US6156768A (en) | 1992-10-30 | 2000-12-05 | G. D. Searle & Co. | Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| WO1994018192A1 (en) | 1993-02-12 | 1994-08-18 | Merck & Co., Inc. | Piperazine derivatives as hiv protease inhibitors |
| TW281669B (US06559137-20030506-C00232.png) | 1993-02-17 | 1996-07-21 | Chugai Pharmaceutical Co Ltd | |
| AU7669794A (en) | 1993-08-24 | 1995-03-21 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
| IL110898A0 (en) | 1993-09-10 | 1994-11-28 | Narhex Australia Pty Ltd | Polar-substituted hydrocarbons |
| IL111584A0 (en) | 1993-11-18 | 1995-01-24 | Merck & Co Inc | Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them |
| US5527829A (en) | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| DE19506742A1 (de) | 1995-02-27 | 1996-08-29 | Bayer Ag | Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen |
| US5691372A (en) | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
| US5750493A (en) | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| US5646180A (en) | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
| US6180634B1 (en) | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
| CA2316218A1 (en) * | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| TNSN00027A1 (fr) * | 1999-02-12 | 2005-11-10 | Vertex Pharma | Inhibiteurs de l'aspartyle protease |
-
1997
- 1997-12-24 US US08/998,050 patent/US6436989B1/en not_active Expired - Lifetime
-
1998
- 1998-03-09 PL PL342113A patent/PL202845B1/pl unknown
- 1998-03-09 SK SK966-2000A patent/SK287123B6/sk not_active IP Right Cessation
- 1998-03-09 IL IL13694198A patent/IL136941A0/xx active IP Right Review Request
- 1998-03-09 KR KR10-2000-7007113A patent/KR100520737B1/ko not_active IP Right Cessation
- 1998-03-09 ID IDW20001413A patent/ID24962A/id unknown
- 1998-03-09 ME MEP-820/08A patent/MEP82008A/xx unknown
- 1998-03-09 EA EA200000703A patent/EA003509B1/ru not_active IP Right Cessation
- 1998-03-09 AP APAP/P/2000/001850A patent/AP1172A/en active
- 1998-03-09 AU AU65466/98A patent/AU755087B2/en not_active Expired
- 1998-03-09 WO PCT/US1998/004595 patent/WO1999033815A1/en active Application Filing
- 1998-03-09 CZ CZ20002363A patent/CZ301653B6/cs not_active IP Right Cessation
- 1998-03-09 TR TR2000/02615T patent/TR200002615T2/xx unknown
- 1998-03-09 NZ NZ505776A patent/NZ505776A/xx not_active IP Right Cessation
- 1998-03-09 CN CNA2009101453192A patent/CN101565412A/zh active Pending
- 1998-03-09 CN CNB988132338A patent/CN100503589C/zh not_active Expired - Lifetime
- 1998-03-09 RS YU39800A patent/RS52483B/en unknown
- 1998-03-09 EE EEP200000385A patent/EE04466B1/xx unknown
- 1998-03-09 BR BR9814480-4A patent/BR9814480A/pt not_active Application Discontinuation
- 1998-03-09 HU HU0101831A patent/HU229596B1/hu active Protection Beyond IP Right Term
- 1998-03-10 AT AT98104292T patent/ATE382042T1/de active
- 1998-03-10 PT PT98104292T patent/PT933372E/pt unknown
- 1998-03-10 DE DE69838903T patent/DE69838903T2/de not_active Expired - Lifetime
- 1998-03-10 ES ES98104292T patent/ES2299193T3/es not_active Expired - Lifetime
- 1998-03-10 DE DE122008000021C patent/DE122008000021I2/de active Active
- 1998-03-10 EP EP07024817A patent/EP1944300A3/en not_active Withdrawn
- 1998-03-10 JP JP05870598A patent/JP3736964B2/ja not_active Expired - Lifetime
- 1998-03-10 CA CA002231700A patent/CA2231700C/en not_active Expired - Lifetime
- 1998-03-10 SI SI9830903T patent/SI0933372T1/sl unknown
- 1998-03-10 DK DK98104292T patent/DK0933372T3/da active
- 1998-03-10 EP EP98104292A patent/EP0933372B1/en not_active Expired - Lifetime
- 1998-09-03 UA UA2000074456A patent/UA72733C2/uk unknown
- 1998-12-22 MY MYPI98005827A patent/MY131525A/en unknown
- 1998-12-22 TW TW087121460A patent/TW486474B/zh not_active IP Right Cessation
- 1998-12-23 ZA ZA9811830A patent/ZA9811830B/xx unknown
- 1998-12-23 PE PE1998001275A patent/PE20000048A1/es not_active IP Right Cessation
- 1998-12-23 CO CO98076458A patent/CO4990992A1/es unknown
- 1998-12-23 AR ARP980106679A patent/AR017965A1/es active IP Right Grant
-
2000
- 2000-02-03 HK HK00100695A patent/HK1021737A1/xx not_active IP Right Cessation
- 2000-06-22 IS IS5546A patent/IS2817B/is unknown
- 2000-06-22 IL IL136941A patent/IL136941A/en not_active IP Right Cessation
- 2000-06-23 NO NO20003304A patent/NO326265B1/no not_active IP Right Cessation
- 2000-06-23 US US09/602,494 patent/US6559137B1/en not_active Expired - Lifetime
- 2000-06-23 OA OA1200000187A patent/OA11468A/en unknown
- 2000-07-24 BG BG104631A patent/BG64869B1/bg unknown
-
2003
- 2003-02-19 US US10/370,171 patent/US6838474B2/en not_active Expired - Lifetime
-
2004
- 2004-10-04 US US10/958,223 patent/US7592368B2/en not_active Expired - Fee Related
-
2005
- 2005-07-13 JP JP2005205007A patent/JP4282639B2/ja not_active Expired - Lifetime
-
2008
- 2008-03-26 NL NL300339C patent/NL300339I2/nl unknown
- 2008-04-02 LU LU91426C patent/LU91426I2/fr unknown
- 2008-04-17 FR FR08C0015C patent/FR08C0015I2/fr active Active
-
2009
- 2009-01-27 JP JP2009016033A patent/JP2009102400A/ja not_active Withdrawn
- 2009-04-22 NO NO2009008C patent/NO2009008I2/no not_active IP Right Cessation
- 2009-07-16 US US12/504,243 patent/US20100124543A1/en not_active Abandoned
-
2014
- 2014-07-18 HU HUS1400042C patent/HUS1400042I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4990992A1 (es) | Profarmacos de compuestos de sulfonamida como inhibidores de aspartil proteasa | |
| CO5261510A1 (es) | Inhibidores de aspartil proteasa | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR086181A2 (es) | Metodo para preparar inhibidores macrociclicos inhibidores de serina proteasas del virus de la hepatitis c | |
| CO5160337A1 (es) | Inhibidores de aspartilo proteasa proteasa | |
| AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR039665A1 (es) | Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR119494A1 (es) | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS | |
| AR070513A1 (es) | Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR060606A1 (es) | Compuestos organicos derivados de purina y un proceso de preparacion | |
| CO5700782A2 (es) | Derivados de quinuckidina que se enlazan con los receptores muscarinicos m3 | |
| CO6160307A2 (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
| AR114828A1 (es) | Compuestos de pteridinona y sus usos | |
| CO5640041A2 (es) | Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR117472A1 (es) | Inhibidores de tienopiridina de ripk2 | |
| CO6400145A2 (es) | Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica | |
| AR047532A1 (es) | Derivados de tiazolilimidazol, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus usos como inhibidores de la proteina de transferencia de trigliceridos microsomales. | |
| AR111826A1 (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| AR086084A1 (es) | Composicion oftalmica acuosa |